No Increased Bleeding Events with Continuation of Oral Anticoagulation Therapy for Patients Undergoing Cardiac Device Procedure
Authors:
- David J. BradleyDBDavid J. Bradley
- Hon‐Chi LeeHLHon‐Chi Lee
- 16 March 2011
- journal article
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 34 (7) , 868-874
Abstract
Background: Switching warfarin for heparin has been a practice for managing periprocedural anticoagulation in high‐risk patients undergoing device‐related procedures. We sought to investigate whether continuation of warfarin sodium therapy without heparin bridging is safe and, when it is continued, the optimal international normalized ratio (INR) without increased bleeding risk at time of device‐related procedure. Methods and Results: We retrospectively studied 766 consecutive patients taking warfarin long term who underwent device‐related procedures. Patients were grouped by treatment: discontinued warfarin (−warfarin, n = 243), no interruption of warfarin (+warfarin, n = 324), and discontinued warfarin with heparin bridging (+heparin, n = 199). The study primary endpoint was systemic bleeding or formation of moderate or severe pocket hematoma within 30 days of the procedure. Thirty‐one (4%) patients had bleeding events, including pocket hematoma in 29 patients. The bleeding events occurred more often for +heparin (7.0%) than −warfarin (2.1%) or +warfarin (3.7%, P = 0.029). For +warfarin group, INR of 2.0–2.5 at time of procedure did not increase bleeding risk compared with INR less than 1.5 (3.7% vs 3.4%; P = 0.72), but INR greater than 2.5 increased the bleeding risk (10.0% vs 3.4%; P = 0.029). Concomitant aspirin use with warfarin significantly increased bleeding risk than warfarin alone (5.6% vs 1.4%, P = 0.02). Median length of hospitalization was significantly shorter for +warfarin than +heparin (1 vs 6 days; P < 0.001). Conclusion: Continuation of oral anticoagulation therapy with an INR level ofKeywords
This publication has 18 references indexed in Scilit:
- Complications of replacing implantable devices in response to advisories: A single center experienceInternational Journal of Cardiology, 2009
- 2008 Focused Update Incorporated Into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart DiseaseJACC, 2008
- Risk Factors Related to Infections of Implanted Pacemakers and Cardioverter-DefibrillatorsCirculation, 2007
- Pocket Hematoma After Pacemaker or Implantable Cardioverter Defibrillator SurgeryChest, 2004
- Pacemaker and Implantable Cardioverter Defibrillator Implantation Without Reversal of Warfarin TherapyPacing and Clinical Electrophysiology, 2004
- Implantation of Pacemakers and Implantable Cardioverter Defibrillators in Orally Anticoagulated PatientsPacing and Clinical Electrophysiology, 2003
- Validation of Clinical Classification Schemes for Predicting StrokeJAMA, 2001
- Outpatient Pacemaker Procedures in Orally Anticoagulated PatientsPacing and Clinical Electrophysiology, 1998
- Long‐Term Thrombosis after Transvenous Permanent Pacemaker ImplantationPacing and Clinical Electrophysiology, 1998
- A 5½ year experience with the St. Jude Medical cardiac valve prosthesisThe Journal of Thoracic and Cardiovascular Surgery, 1985